Cencora (NYSE:COR) Releases FY 2026 Earnings Guidance

Cencora (NYSE:COR) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 17.450-17.600 for the period, compared to the consensus estimate of 17.610. The company issued revenue guidance of $343.8 billion-$350.2 billion, compared to the consensus revenue estimate of $340.7 billion.

Analysts Set New Price Targets

COR has been the subject of several recent research reports. Robert W. Baird set a $415.00 price target on Cencora in a report on Tuesday, January 13th. Mizuho boosted their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. TD Cowen raised their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Wells Fargo & Company increased their price target on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $396.92.

Cencora Price Performance

Shares of COR opened at $351.91 on Friday. The firm has a market capitalization of $68.27 billion, a price-to-earnings ratio of 42.30, a price-to-earnings-growth ratio of 1.69 and a beta of 0.68. The stock’s fifty day moving average is $347.08 and its 200-day moving average is $327.83. Cencora has a one year low of $237.71 and a one year high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same period last year, the company posted $3.73 earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. Equities analysts anticipate that Cencora will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is presently 28.85%.

Insider Activity

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer directly owned 66,726 shares in the company, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 20,316 shares of company stock worth $7,151,265. Company insiders own 0.38% of the company’s stock.

Institutional Investors Weigh In On Cencora

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marshall Wace LLP raised its stake in shares of Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after purchasing an additional 1,672,762 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after acquiring an additional 1,241,186 shares during the period. Viking Global Investors LP increased its stake in Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after acquiring an additional 1,013,913 shares during the last quarter. State Street Corp lifted its stake in Cencora by 9.3% during the third quarter. State Street Corp now owns 9,190,316 shares of the company’s stock worth $2,872,249,000 after purchasing an additional 782,911 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of Cencora by 228.6% in the second quarter. Ameriprise Financial Inc. now owns 974,505 shares of the company’s stock worth $292,207,000 after acquiring an additional 677,952 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.